We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+9.06%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$14.6B
AUM Growth
+$2.6B
(+22%)
Cap. Flow
+$859M
Cap. Flow
% of AUM
5.88%
Top 10 Holdings %
Top 10 Hldgs %
21.92%
Holding
958
New
131
Increased
364
Reduced
334
Closed
74
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$135M |
| 2 |
Royal Bank of Canada
RY
|
+$120M |
| 3 |
Agilent Technologies
A
|
+$72.5M |
| 4 |
UnitedHealth
UNH
|
+$71.5M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$64.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$90.3M |
| 2 |
Amgen
AMGN
|
+$88.7M |
| 3 |
Allstate
ALL
|
+$52.2M |
| 4 |
Union Pacific
UNP
|
+$47.1M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
+$44.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.42% |
| 2 | Technology | 23.2% |
| 3 | Consumer Discretionary | 9.14% |
| 4 | Financials | 8.63% |
| 5 | Communication Services | 7.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Mercado Libre
MELI
$91.3B
| $33.7M | 0.23% |
21,637
-2,559
| -11% | -$3.76M |
|
|
XIFR
102
XPLR Infrastructure LP
XIFR
$1.18B
| $33.7M | 0.23% |
441,387
+191,490
| +77% | +$13.7M |
|
103
JD.com
JD
$40.8B
| $33.6M | 0.23% |
420,659
-209,745
| -33% | -$15.8M |
|
104
Target
TGT
$62.1B
| $32.6M | 0.22% |
120,237
+88,463
| +278% | +$19.4M |
|
105
Prologis
PLD
$138B
| $31.7M | 0.22% |
265,477
+62,611
| +31% | +$7.32M |
|
106
Keysight
KEYS
$54.5B
| $31.6M | 0.22% |
204,795
-108,537
| -35% | -$15.7M |
|
107
Idexx Laboratories
IDXX
$42.9B
| $31.5M | 0.22% |
49,926
+43,592
| +688% | +$24.1M |
|
108
Berkshire Hathaway Class B
BRK.B
$1.07T
| $31.4M | 0.22% |
113,090
+73,325
| +184% | +$20.5M |
|
|
INFO
109
DELISTED
IHS Markit Ltd. Common Shares
INFO
| $31.2M | 0.21% |
276,529
+103,422
| +60% | +$11M |
|
110
Lam Research
LRCX
$382B
| $31M | 0.21% |
458,840
+320,100
| +231% | +$20.2M |
|
111
Darling Ingredients
DAR
$9.93B
| $30.8M | 0.21% |
456,516
+456,497
| +2,402,616% | +$32.2M |
|
112
Synopsys
SNPS
$71.5B
| $30.6M | 0.21% |
110,981
+15,934
| +17% | +$4.04M |
|
113
Vipshop
VIPS
$6.84B
| $30.4M | 0.21% |
1,513,624
-86,470
| -5% | -$2.17M |
|
114
Scotiabank
BNS
$106B
| $30.2M | 0.21% |
464,238
+414,849
| +840% | +$26.8M |
|
|
ATVI
115
DELISTED
Activision Blizzard
ATVI
| $29.9M | 0.2% |
313,429
-51,107
| -14% | -$4.84M |
|
|
WCN
116
Waste Connections
WCN
$42.8B
| $29.8M | 0.2% |
249,768
+81,149
| +48% | +$9.66M |
|
|
EXAS
117
DELISTED
Exact Sciences
EXAS
| $29.7M | 0.2% |
238,992
+63,118
| +36% | +$7.53M |
|
118
Alnylam Pharmaceuticals
ALNY
$36.3B
| $29.6M | 0.2% |
174,822
+12,264
| +8% | +$1.8M |
|
119
Costco
COST
$415B
| $29.3M | 0.2% |
73,998
+38,984
| +111% | +$14.7M |
|
120
Chipotle Mexican Grill
CMG
$40.8B
| $28.7M | 0.2% |
926,900
+654,450
| +240% | +$18.7M |
|
121
Eli Lilly
LLY
$1.07T
| $28M | 0.19% |
121,791
-78,944
| -39% | -$15.9M |
|
122
CVS Health
CVS
$137B
| $27.9M | 0.19% |
328,132
+78,903
| +32% | +$6.46M |
|
123
Enphase Energy
ENPH
$4.84B
| $27.9M | 0.19% |
151,930
-10,352
| -6% | -$1.52M |
|
124
BridgeBio Pharma
BBIO
$16.5B
| $27.8M | 0.19% |
+455,285
| New | +$26M |
|
125
Bio-Techne
TECH
$11.2B
| $27.6M | 0.19% |
245,252
-187,880
| -43% | -$19.8M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2021 Portfolio in Review
As of Q2 2021, Candriam SCA held 958 positions worth $14.6B, up 22% from $12B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Candriam SCA deployed $859M of net new capital in Q2 2021, opening 131 new positions and adding to 364 existing holdings. Its largest new stake was SailPoint Technologies Holdings, Inc. Common Stock: 738,233 shares worth $37.7M.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 34% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $90.3M trimmed.
- Candriam SCA's largest Q2 2021 buy was SailPoint Technologies Holdings, Inc. Common Stock: 738,233 shares worth $37.7M.
- Candriam SCA added most to Microsoft in Q2 2021, an estimated $135M increase.
- Candriam SCA's biggest Q2 2021 reduction was Bristol-Myers Squibb, cutting an estimated $90.3M.
- Candriam SCA fully exited Tenable Holdings in Q2 2021, selling an estimated $31.6M.
- Candriam SCA's ten largest holdings make up 22% of its $14.6B portfolio in Q2 2021.
- Candriam SCA opened 131 new positions and closed 74 in Q2 2021.
- Candriam SCA's portfolio value rose 22% quarter-over-quarter to $14.6B.
Based on Candriam SCA's 13F filing for Q2 2021, filed 20 Jul 2021.